Here is the synopsis of our sample research paper on GENENTECH, NOVARTIS, TANOX AND MORALITY. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
This 6-page paper examines the ethics behind Genetech and Novartis' blocking of partner Tanox's experiments on TNX-901, a drug tested for prevention of peanut allergies. The paper explains why the fight against testing and release of this drug was not a moral one.
Page Count:
6 pages (~225 words per page)
File: D0_MTtanoxa.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
good" definition and that of making profits. This was definitely the case when Genentech and Novartis blocked the development of TNX-190, a drug that might help people who suffer from
peanut allergies. In this paper, well examine the justification of Genentech and Novartis blocking of Tanoxs efforts with the drug, and determine if there was enough economic incentive for these
companies to do so. According to the Wall Street Journal article "Silent Treatment: How Genentech, Novartis, stifled a promising drug" (written by David
Hamilton and printed in the April 5, 2005 version of the publication), more than 1.5 million Americans have an allergy to peanuts, an allergy that can sometimes be fatal. Furthermore,
according to the Food Allergy and Anaphylaxis Network, such food allergies lead to 30,000 emergency room visits and more than 150 deaths a year -- with many of these allergies
due to peanuts. The drug TNX-901 was supposed to help prevent both allergies and attacks, as a preventative medication. But the problem was
that Tanax, which had proven successful in clinical trials, ended development because of Genentech Inc.s and Novartis insistence that development of the drug be halted in favor of a Genentech
drug called Xolair. The problem is that while TNX-901 had proven effective in trials, Xolair had not, especially against peanut allergies. Tanox refused, and Novartis and Genetech (who are Tanoxs
partners) to the company to court. The case took five years to solve and cost more than $100 million in legal fees. While
sometimes drug companies are known to cancel in-house projects to either prevent competition with a drug company that already sells a particular medication (or could possibly be a patent-infringing situation),
...